Warning letter · FDA Warning Letters, Historical Archive

Peak Nootropics LLC (aka Advanced Nootropics): FDA Warning Letter 557887 (Feb 5, 2019)

Agency action: Feb 5, 2019Record ID: fda_warning_-b3a5aafa01007c8d
View official source ↗

What happened

Original notice title

Peak Nootropics LLC aka Advanced Nootropics MARCS-CMS 557887, February 05, 2019

From the archived source record

The substance is believed to reduce the risk of ischemic stroke as well as minimize post-stroke damages to the brain. Early studies on the drug claim that it is a good supplement to consider for reducing the risk of developing bladder cancer.” “Those that suffer from high cholesterol can consider consuming this natural herb to reduce the risk of developing heart ailments. A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Accordingly, Adrafinil, Aniracetam, Bacopa Monnieri, L-Dopa, L-Theanine, Noopept, Phenylpiracetam, Piracetam, Rhodiola Rosea, and Uridine fail to bear adequate directions for their intended uses and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)]. The violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. You should take prompt action to correct the violations cited in this letter. Failure to correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction. Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
Historical warning letter; closeout not established by annual index
Source checked
Jul 16, 2026
Record revision
615c52b9440f

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
Adrafinil; Aniracetam; Bacopa Monnieri; L-Dopa; L-Theanine; Noopept; Oxiracetam; Phenibut; Phenylpiracetam; Piracetam; [1] Rhodiola Rosea; Pramiracetam; Rhodiola Rosea
Company
Peak Nootropics LLC (aka Advanced Nootropics)
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.